Provided by Tiger Trade Technology Pte. Ltd.

Cumberland Pharmaceuticals

3.91
+0.32008.91%
Post-market: 3.90-0.0100-0.26%17:52 EST
Volume:102.77K
Turnover:395.42K
Market Cap:58.48M
PE:-16.65
High:3.98
Open:3.54
Low:3.54
Close:3.59
52wk High:7.25
52wk Low:1.85
Shares:14.96M
Float Shares:7.97M
Volume Ratio:0.28
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2349
EPS(LYR):-0.4609
ROE:-13.28%
ROA:-2.86%
PB:2.24
PE(LYR):-8.48

Loading ...

Cumberland Pharmaceuticals Wins Fast Track for Ifetroban

TIPRANKS
·
Feb 05

BUZZ-Cumberland jumps as heart drug for muscle‑wasting disease gets FDA's fast-track tag

Reuters
·
Feb 04

Cumberland receives fast track designation for DMD oral therapy from FDA

TIPRANKS
·
Feb 04

Cumberland Pharmaceuticals Wins FDA Fast Track for Ifetroban in Duchenne Muscular Dystrophy

Reuters
·
Feb 04

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for Its Ifetroban Duchenne Muscular Dystrophy Program

THOMSON REUTERS
·
Feb 04

Cumberland Pharmaceuticals Leads 3 Promising Penny Stocks

Simply Wall St.
·
Dec 17, 2025

Cumberland Pharmaceuticals Amends Credit Agreement With Pinnacle Bank, Extends Maturity to 2027

Reuters
·
Nov 24, 2025

Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Expansions

TIPRANKS
·
Nov 05, 2025

Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln

Reuters
·
Nov 05, 2025

Cumberland Q3 Adj. EPS $(0.06) Down From $(0.02) YoY, Sales $8.292M Down From $9.086M YoY

Benzinga
·
Nov 05, 2025

Cumberland Pharmaceuticals reports $30.8 million year-to-date revenue, 12% increase

Reuters
·
Nov 05, 2025

Cumberland Pharmaceuticals Q3 Operating Expenses USD 10.3 Million

THOMSON REUTERS
·
Nov 05, 2025

Cumberland Pharmaceuticals Reports 12% Year-to-Date Revenue Growth

THOMSON REUTERS
·
Nov 05, 2025

Cumberland Pharmaceuticals Inc. to Release Q3 2025 Financial Results

Reuters
·
Oct 29, 2025

Cumberland Pharmaceuticals Partners with RedHill for Talicia

TIPRANKS
·
Oct 21, 2025

BRIEF-CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Reuters
·
Oct 20, 2025

Cumberland Pharmaceuticals and RedHill Biopharma Launch Joint Venture to Commercialize Talicia

Reuters
·
Oct 20, 2025

Cumberland Phamaceuticals Announces the Addition of an Established FDA Approved Product to Its Commercial Portfolio

THOMSON REUTERS
·
Oct 20, 2025

BRIEF-RedHill's Talicia Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Reuters
·
Oct 20, 2025

Redhill Biopharma Ltd - Cumberland Invests $4 Mln for 30% Stake in Co's Global Talicia Business

THOMSON REUTERS
·
Oct 20, 2025